Adverse events assessed as at least possibly related to bortezomib
| CTC system organ class . | CTC adverse event term . | CTC adverse event grade . | All . | |||
|---|---|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | |||
| N . | N . | N . | N . | N . | ||
| Blood and lymphatic system disorders | Anemia | 0 | 5 | 9 | 0 | 14 |
| Febrile neutropenia | 0 | 0 | 2 | 0 | 2 | |
| Eye disorders | Blurred vision | 1 | 0 | 0 | 0 | 1 |
| Gastrointestinal disorders | Abdominal pain | 0 | 0 | 1 | 0 | 1 |
| Constipation | 1 | 1 | 0 | 0 | 2 | |
| Diarrhea | 1 | 1 | 2 | 0 | 4 | |
| Mucositis oral | 1 | 1 | 0 | 0 | 2 | |
| Nausea | 4 | 0 | 0 | 0 | 4 | |
| Vomiting | 3 | 0 | 0 | 0 | 3 | |
| General disorders and administration site conditions | Fatigue | 4 | 0 | 1 | 0 | 5 |
| Fever | 1 | 0 | 0 | 0 | 1 | |
| Injection site reaction | 1 | 0 | 0 | 0 | 1 | |
| Pain | 1 | 0 | 0 | 0 | 1 | |
| Infections and infestations | Mucosal infection | 1 | 0 | 0 | 0 | 1 |
| Investigations | Alkaline phosphatase increase | 2 | 0 | 0 | 0 | 2 |
| Lymphocyte count decreased | 1 | 0 | 3 | 2 | 6 | |
| Neutrophil count decreased | 0 | 2 | 2 | 8 | 12 | |
| Platelet count decreased | 0 | 1 | 4 | 7 | 12 | |
| White blood cell decreased | 0 | 2 | 1 | 7 | 10 | |
| Metabolism and nutrition disorders | Anorexia | 1 | 1 | 0 | 0 | 2 |
| Hypokalemia | 0 | 0 | 1 | 0 | 1 | |
| Hypomagnesemia | 1 | 0 | 0 | 0 | 1 | |
| Hyponatremia | 1 | 0 | 0 | 0 | 1 | |
| Hypophosphatemia | 0 | 1 | 4 | 0 | 5 | |
| Nervous system disorders | Dysgeusia | 1 | 0 | 0 | 0 | 1 |
| Headache | 2 | 1 | 0 | 0 | 3 | |
| Neuralgia | 1 | 0 | 1 | 0 | 2 | |
| Paresthesia | 1 | 0 | 0 | 0 | 1 | |
| Peripheral sensory neuropathy | 2 | 0 | 0 | 0 | 2 | |
| Seizure | 0 | 0 | 1 | 0 | 1 | |
| Syncope | 0 | 0 | 1 | 0 | 1 | |
| Psychiatric disorders | Insomnia | 0 | 1 | 0 | 0 | 1 |
| Respiratory disorders | Cough | 1 | 0 | 0 | 0 | 1 |
| Skin and subcutaneous tissue disorders | Alopecia | 0 | 1 | 0 | 0 | 1 |
| Vascular disorders | Hypotension | 0 | 0 | 2 | 0 | 2 |
| CTC system organ class . | CTC adverse event term . | CTC adverse event grade . | All . | |||
|---|---|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | |||
| N . | N . | N . | N . | N . | ||
| Blood and lymphatic system disorders | Anemia | 0 | 5 | 9 | 0 | 14 |
| Febrile neutropenia | 0 | 0 | 2 | 0 | 2 | |
| Eye disorders | Blurred vision | 1 | 0 | 0 | 0 | 1 |
| Gastrointestinal disorders | Abdominal pain | 0 | 0 | 1 | 0 | 1 |
| Constipation | 1 | 1 | 0 | 0 | 2 | |
| Diarrhea | 1 | 1 | 2 | 0 | 4 | |
| Mucositis oral | 1 | 1 | 0 | 0 | 2 | |
| Nausea | 4 | 0 | 0 | 0 | 4 | |
| Vomiting | 3 | 0 | 0 | 0 | 3 | |
| General disorders and administration site conditions | Fatigue | 4 | 0 | 1 | 0 | 5 |
| Fever | 1 | 0 | 0 | 0 | 1 | |
| Injection site reaction | 1 | 0 | 0 | 0 | 1 | |
| Pain | 1 | 0 | 0 | 0 | 1 | |
| Infections and infestations | Mucosal infection | 1 | 0 | 0 | 0 | 1 |
| Investigations | Alkaline phosphatase increase | 2 | 0 | 0 | 0 | 2 |
| Lymphocyte count decreased | 1 | 0 | 3 | 2 | 6 | |
| Neutrophil count decreased | 0 | 2 | 2 | 8 | 12 | |
| Platelet count decreased | 0 | 1 | 4 | 7 | 12 | |
| White blood cell decreased | 0 | 2 | 1 | 7 | 10 | |
| Metabolism and nutrition disorders | Anorexia | 1 | 1 | 0 | 0 | 2 |
| Hypokalemia | 0 | 0 | 1 | 0 | 1 | |
| Hypomagnesemia | 1 | 0 | 0 | 0 | 1 | |
| Hyponatremia | 1 | 0 | 0 | 0 | 1 | |
| Hypophosphatemia | 0 | 1 | 4 | 0 | 5 | |
| Nervous system disorders | Dysgeusia | 1 | 0 | 0 | 0 | 1 |
| Headache | 2 | 1 | 0 | 0 | 3 | |
| Neuralgia | 1 | 0 | 1 | 0 | 2 | |
| Paresthesia | 1 | 0 | 0 | 0 | 1 | |
| Peripheral sensory neuropathy | 2 | 0 | 0 | 0 | 2 | |
| Seizure | 0 | 0 | 1 | 0 | 1 | |
| Syncope | 0 | 0 | 1 | 0 | 1 | |
| Psychiatric disorders | Insomnia | 0 | 1 | 0 | 0 | 1 |
| Respiratory disorders | Cough | 1 | 0 | 0 | 0 | 1 |
| Skin and subcutaneous tissue disorders | Alopecia | 0 | 1 | 0 | 0 | 1 |
| Vascular disorders | Hypotension | 0 | 0 | 2 | 0 | 2 |
CTC, Common Toxicity Criteria.